RAS genes and cancer

Tikvah K. Hayes; Jeran K. Stratford; Andrea Wang-Gillam; Channing J. Der

doi:10.1007/978-3-7091-1806-1_7

RAS genes and cancer

Tikvah K. Hayes, Jeran K. Stratford, Andrea Wang-Gillam, Channing J. Der

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The three RAS genes (HRAS, KRAS, and NRAS) comprise the most commonly mutated oncogene family in human cancer. RAS genes encode highly related small GTPases that are key regulators of cytoplasmic signaling networks that include the Raf-MEK-ERK mitogen-activated protein kinase cascade and the PI3K-Akt signaling cascade. There is increasing evidence that all RAS mutations are not created equal and that mutation specific therapies may be needed, that there will not be a one size fits all anti-Ras therapy. In this chapter, we summarize the frequency and nature of RAS mutations in human cancers, with a focus on the two cancers with the highest frequency of RAS mutations, pancreatic ductal adenocarcinoma (95 %), and colorectal (40 %) cancers.

Original language	English
Title of host publication	Ras Superfamily Small G Proteins
Subtitle of host publication	Biology and Mechanisms 1: General Features, Signaling
Publisher	Springer-Verlag Wien
Pages	157-171
Number of pages	15
ISBN (Electronic)	9783709118061
ISBN (Print)	3709118050, 9783709118054
DOIs	https://doi.org/10.1007/978-3-7091-1806-1_7
State	Published - May 1 2014

Keywords

Colorectal cancer
ERK
HRAS
KRAS
NRAS
PI3K
Pancreatic cancer
Raf

Access to Document

10.1007/978-3-7091-1806-1_7

Cite this

@inbook{4f76fd860bfb482d8f065a5d48275abf,

title = "RAS genes and cancer",

abstract = "The three RAS genes (HRAS, KRAS, and NRAS) comprise the most commonly mutated oncogene family in human cancer. RAS genes encode highly related small GTPases that are key regulators of cytoplasmic signaling networks that include the Raf-MEK-ERK mitogen-activated protein kinase cascade and the PI3K-Akt signaling cascade. There is increasing evidence that all RAS mutations are not created equal and that mutation specific therapies may be needed, that there will not be a one size fits all anti-Ras therapy. In this chapter, we summarize the frequency and nature of RAS mutations in human cancers, with a focus on the two cancers with the highest frequency of RAS mutations, pancreatic ductal adenocarcinoma (95 %), and colorectal (40 %) cancers.",

keywords = "Colorectal cancer, ERK, HRAS, KRAS, NRAS, PI3K, Pancreatic cancer, Raf",

author = "Hayes, {Tikvah K.} and Stratford, {Jeran K.} and Andrea Wang-Gillam and Der, {Channing J.}",

year = "2014",

month = may,

day = "1",

doi = "10.1007/978-3-7091-1806-1_7",

language = "English",

isbn = "3709118050",

pages = "157--171",

booktitle = "Ras Superfamily Small G Proteins",

publisher = "Springer-Verlag Wien",

}

TY - CHAP

T1 - RAS genes and cancer

AU - Hayes, Tikvah K.

AU - Stratford, Jeran K.

AU - Wang-Gillam, Andrea

AU - Der, Channing J.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - The three RAS genes (HRAS, KRAS, and NRAS) comprise the most commonly mutated oncogene family in human cancer. RAS genes encode highly related small GTPases that are key regulators of cytoplasmic signaling networks that include the Raf-MEK-ERK mitogen-activated protein kinase cascade and the PI3K-Akt signaling cascade. There is increasing evidence that all RAS mutations are not created equal and that mutation specific therapies may be needed, that there will not be a one size fits all anti-Ras therapy. In this chapter, we summarize the frequency and nature of RAS mutations in human cancers, with a focus on the two cancers with the highest frequency of RAS mutations, pancreatic ductal adenocarcinoma (95 %), and colorectal (40 %) cancers.

AB - The three RAS genes (HRAS, KRAS, and NRAS) comprise the most commonly mutated oncogene family in human cancer. RAS genes encode highly related small GTPases that are key regulators of cytoplasmic signaling networks that include the Raf-MEK-ERK mitogen-activated protein kinase cascade and the PI3K-Akt signaling cascade. There is increasing evidence that all RAS mutations are not created equal and that mutation specific therapies may be needed, that there will not be a one size fits all anti-Ras therapy. In this chapter, we summarize the frequency and nature of RAS mutations in human cancers, with a focus on the two cancers with the highest frequency of RAS mutations, pancreatic ductal adenocarcinoma (95 %), and colorectal (40 %) cancers.

KW - Colorectal cancer

KW - ERK

KW - HRAS

KW - KRAS

KW - NRAS

KW - PI3K

KW - Pancreatic cancer

KW - Raf

UR - http://www.scopus.com/inward/record.url?scp=84930825761&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1806-1_7

DO - 10.1007/978-3-7091-1806-1_7

M3 - Chapter

AN - SCOPUS:84930825761

SN - 3709118050

SN - 9783709118054

SP - 157

EP - 171

BT - Ras Superfamily Small G Proteins

PB - Springer-Verlag Wien

ER -

RAS genes and cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this